Michael Galambos

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

David Jones, Pol Boudes, Mark G. Swain et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 186 citations

Medicine, Pharmacology, Pharmacotherapy +12

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Christopher L. Bowlus, Michael Galambos, Richard Aspinall et al. · Journal of Hepatology · 2022 · 79 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +10

Noncirrhotic Portal Hypertension in Patients With Human Immunodeficiency Virus–1 Infection

Sophia Saifee, Dean W. Joelson, James Braude et al. · Clinical Gastroenterology and Hepatology · 2008 · 72 citations

Medicine, Internal Medicine, Pathology +13